In the real world, dupilumab has been as effective as the results in clinical trials, and patients are seeing low exacerbation rates, emergency department visits, and hospitalizations, explained Neal Jain, MD, FAAP, FAAAAI, director of research at Arizona Allergy & Immunology Research and a co-owner of Arcadia Allergy & Asthma and San Tan Allergy & Asthma.